C‐reactive protein lowering with rosuvastatin in the METEOR study
. Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Cari...
Gespeichert in:
| Veröffentlicht in: | Journal of internal medicine 2010-08, Vol.268 (2), p.155-161 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | 2 |
| container_start_page | 155 |
| container_title | Journal of internal medicine |
| container_volume | 268 |
| creator | Peters, S. A. E. Palmer, M. K. Grobbee, D. E. Crouse, J. R. O’Leary, D. H. Raichlen, J. S. Bots, M. L. |
| description | . Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Caritas Carney Hospital, Boston, MA, USA; AstraZeneca, Wilmington, DE, USA). C‐reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155–161.
Objectives. In addition to its LDL‐C‐lowering effects, statin treatment reduces the level of C‐reactive protein (CRP). Long‐term data on this effect in low‐risk populations are limited. Furthermore, whether the CRP reduction is a consequence of LDL‐C lowering or occurs independently remains unclear. We studied these aspects in the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study, a randomized placebo‐controlled trial amongst 984 low‐risk subjects.
Methods. METEOR is a randomized placebo‐controlled trial that evaluated the effect of 40 mg of rosuvastatin on 2‐year change in carotid intima media thickness (CIMT) amongst 984 low‐risk patients (10‐year Framingham risk |
| doi_str_mv | 10.1111/j.1365-2796.2010.02230.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733996168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733996168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3990-b02abb25d447deb0ef78f549c819b9a81cadc2a8fe4ddb0dceac90eb8763967f3</originalsourceid><addsrcrecordid>eNqNkN9KwzAUh4Mobk5fQXojXrWeJG3a3AhSpk42BjKvQ5qmrqNrtWn3585H8Bl9ElM3560hkJDznZwfH0IOBg_bdbPwMGWBS0LOPAL2FQih4G2OUP9QOEZ94IHvsohAD50ZswDAFBicoh4BHxMa0j6K46-Pz1pL1eQr7bzVVaPz0imqta7z8tVZ583cqSvTrqRpZGNLdjdz7UyGs-H02TFNm27P0UkmC6Mv9ucAvdwPZ_GjO54-jOK7saso5-AmQGSSkCD1_TDVCegsjLLA5yrCPOEywkqmisgo036aJpAqm4qDTqKQUc7CjA7Q9e5fG_O91aYRy9woXRSy1FVrREjtHIZZZMloRyqb3dQ6E291vpT1VmAQnUGxEJ0o0YkSnUHxY1BsbOvlfkibLHV6aPxVZoGrPSCNkkVWy1Ll5o8jnJGQBpa73XHrvNDbfwcQT9PRpLvSb4mLjc8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733996168</pqid></control><display><type>article</type><title>C‐reactive protein lowering with rosuvastatin in the METEOR study</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Peters, S. A. E. ; Palmer, M. K. ; Grobbee, D. E. ; Crouse, J. R. ; O’Leary, D. H. ; Raichlen, J. S. ; Bots, M. L.</creator><creatorcontrib>Peters, S. A. E. ; Palmer, M. K. ; Grobbee, D. E. ; Crouse, J. R. ; O’Leary, D. H. ; Raichlen, J. S. ; Bots, M. L.</creatorcontrib><description>. Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Caritas Carney Hospital, Boston, MA, USA; AstraZeneca, Wilmington, DE, USA). C‐reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155–161.
Objectives. In addition to its LDL‐C‐lowering effects, statin treatment reduces the level of C‐reactive protein (CRP). Long‐term data on this effect in low‐risk populations are limited. Furthermore, whether the CRP reduction is a consequence of LDL‐C lowering or occurs independently remains unclear. We studied these aspects in the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study, a randomized placebo‐controlled trial amongst 984 low‐risk subjects.
Methods. METEOR is a randomized placebo‐controlled trial that evaluated the effect of 40 mg of rosuvastatin on 2‐year change in carotid intima media thickness (CIMT) amongst 984 low‐risk patients (10‐year Framingham risk <10%) with modest CIMT (CIMT ≥ 1.2 and <3.5 mm) and elevated LDL‐C. CRP levels were measured at baseline and after 2 years of treatment.
Results. Median baseline CRP was 1.4 mg L–1. Rosuvastatin lowered CRP significantly compared with placebo: −36% in the rosuvastatin group versus no change in the placebo group. There was no relation between change in CRP and change in LDL‐C (Spearman correlation: 0.08; SE: 0.04). Stratified analyses showed that the CRP‐lowering effect was present amongst all strata of baseline characteristics, including baseline lipids and CRP levels. However, the magnitude of CRP reduction was larger amongst women and participants older than 60 years.
Conclusions. Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL‐C in low‐risk subjects with normal baseline CRP levels and modest CIMT.</description><identifier>ISSN: 0954-6820</identifier><identifier>EISSN: 1365-2796</identifier><identifier>DOI: 10.1111/j.1365-2796.2010.02230.x</identifier><identifier>PMID: 20412373</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Atherosclerosis - blood ; Atherosclerosis - prevention & control ; Biological and medical sciences ; Biomarkers - blood ; C-Reactive Protein - metabolism ; Carotid Arteries - drug effects ; Carotid Arteries - pathology ; carotid intima media thickness ; Cholesterol, LDL - blood ; Cholesterol, LDL - drug effects ; clinical trials ; Double-Blind Method ; Female ; Fluorobenzenes - pharmacology ; Fluorobenzenes - therapeutic use ; General aspects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; inflammation ; Male ; Medical sciences ; Middle Aged ; preventive medicine ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Rosuvastatin Calcium ; statins ; Sulfonamides - pharmacology ; Sulfonamides - therapeutic use ; Tunica Intima - drug effects ; Tunica Intima - pathology ; Tunica Media - drug effects ; Tunica Media - pathology ; ultrasound</subject><ispartof>Journal of internal medicine, 2010-08, Vol.268 (2), p.155-161</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3990-b02abb25d447deb0ef78f549c819b9a81cadc2a8fe4ddb0dceac90eb8763967f3</citedby><cites>FETCH-LOGICAL-c3990-b02abb25d447deb0ef78f549c819b9a81cadc2a8fe4ddb0dceac90eb8763967f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2796.2010.02230.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2796.2010.02230.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27922,27923,45572,45573,46407,46831</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22962735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20412373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peters, S. A. E.</creatorcontrib><creatorcontrib>Palmer, M. K.</creatorcontrib><creatorcontrib>Grobbee, D. E.</creatorcontrib><creatorcontrib>Crouse, J. R.</creatorcontrib><creatorcontrib>O’Leary, D. H.</creatorcontrib><creatorcontrib>Raichlen, J. S.</creatorcontrib><creatorcontrib>Bots, M. L.</creatorcontrib><title>C‐reactive protein lowering with rosuvastatin in the METEOR study</title><title>Journal of internal medicine</title><addtitle>J Intern Med</addtitle><description>. Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Caritas Carney Hospital, Boston, MA, USA; AstraZeneca, Wilmington, DE, USA). C‐reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155–161.
Objectives. In addition to its LDL‐C‐lowering effects, statin treatment reduces the level of C‐reactive protein (CRP). Long‐term data on this effect in low‐risk populations are limited. Furthermore, whether the CRP reduction is a consequence of LDL‐C lowering or occurs independently remains unclear. We studied these aspects in the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study, a randomized placebo‐controlled trial amongst 984 low‐risk subjects.
Methods. METEOR is a randomized placebo‐controlled trial that evaluated the effect of 40 mg of rosuvastatin on 2‐year change in carotid intima media thickness (CIMT) amongst 984 low‐risk patients (10‐year Framingham risk <10%) with modest CIMT (CIMT ≥ 1.2 and <3.5 mm) and elevated LDL‐C. CRP levels were measured at baseline and after 2 years of treatment.
Results. Median baseline CRP was 1.4 mg L–1. Rosuvastatin lowered CRP significantly compared with placebo: −36% in the rosuvastatin group versus no change in the placebo group. There was no relation between change in CRP and change in LDL‐C (Spearman correlation: 0.08; SE: 0.04). Stratified analyses showed that the CRP‐lowering effect was present amongst all strata of baseline characteristics, including baseline lipids and CRP levels. However, the magnitude of CRP reduction was larger amongst women and participants older than 60 years.
Conclusions. Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL‐C in low‐risk subjects with normal baseline CRP levels and modest CIMT.</description><subject>Aged</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - prevention & control</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>C-Reactive Protein - metabolism</subject><subject>Carotid Arteries - drug effects</subject><subject>Carotid Arteries - pathology</subject><subject>carotid intima media thickness</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, LDL - drug effects</subject><subject>clinical trials</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fluorobenzenes - pharmacology</subject><subject>Fluorobenzenes - therapeutic use</subject><subject>General aspects</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>inflammation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>preventive medicine</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rosuvastatin Calcium</subject><subject>statins</subject><subject>Sulfonamides - pharmacology</subject><subject>Sulfonamides - therapeutic use</subject><subject>Tunica Intima - drug effects</subject><subject>Tunica Intima - pathology</subject><subject>Tunica Media - drug effects</subject><subject>Tunica Media - pathology</subject><subject>ultrasound</subject><issn>0954-6820</issn><issn>1365-2796</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkN9KwzAUh4Mobk5fQXojXrWeJG3a3AhSpk42BjKvQ5qmrqNrtWn3585H8Bl9ElM3560hkJDznZwfH0IOBg_bdbPwMGWBS0LOPAL2FQih4G2OUP9QOEZ94IHvsohAD50ZswDAFBicoh4BHxMa0j6K46-Pz1pL1eQr7bzVVaPz0imqta7z8tVZ583cqSvTrqRpZGNLdjdz7UyGs-H02TFNm27P0UkmC6Mv9ucAvdwPZ_GjO54-jOK7saso5-AmQGSSkCD1_TDVCegsjLLA5yrCPOEywkqmisgo036aJpAqm4qDTqKQUc7CjA7Q9e5fG_O91aYRy9woXRSy1FVrREjtHIZZZMloRyqb3dQ6E291vpT1VmAQnUGxEJ0o0YkSnUHxY1BsbOvlfkibLHV6aPxVZoGrPSCNkkVWy1Ll5o8jnJGQBpa73XHrvNDbfwcQT9PRpLvSb4mLjc8</recordid><startdate>201008</startdate><enddate>201008</enddate><creator>Peters, S. A. E.</creator><creator>Palmer, M. K.</creator><creator>Grobbee, D. E.</creator><creator>Crouse, J. R.</creator><creator>O’Leary, D. H.</creator><creator>Raichlen, J. S.</creator><creator>Bots, M. L.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201008</creationdate><title>C‐reactive protein lowering with rosuvastatin in the METEOR study</title><author>Peters, S. A. E. ; Palmer, M. K. ; Grobbee, D. E. ; Crouse, J. R. ; O’Leary, D. H. ; Raichlen, J. S. ; Bots, M. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3990-b02abb25d447deb0ef78f549c819b9a81cadc2a8fe4ddb0dceac90eb8763967f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - prevention & control</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>C-Reactive Protein - metabolism</topic><topic>Carotid Arteries - drug effects</topic><topic>Carotid Arteries - pathology</topic><topic>carotid intima media thickness</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, LDL - drug effects</topic><topic>clinical trials</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fluorobenzenes - pharmacology</topic><topic>Fluorobenzenes - therapeutic use</topic><topic>General aspects</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>inflammation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>preventive medicine</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rosuvastatin Calcium</topic><topic>statins</topic><topic>Sulfonamides - pharmacology</topic><topic>Sulfonamides - therapeutic use</topic><topic>Tunica Intima - drug effects</topic><topic>Tunica Intima - pathology</topic><topic>Tunica Media - drug effects</topic><topic>Tunica Media - pathology</topic><topic>ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peters, S. A. E.</creatorcontrib><creatorcontrib>Palmer, M. K.</creatorcontrib><creatorcontrib>Grobbee, D. E.</creatorcontrib><creatorcontrib>Crouse, J. R.</creatorcontrib><creatorcontrib>O’Leary, D. H.</creatorcontrib><creatorcontrib>Raichlen, J. S.</creatorcontrib><creatorcontrib>Bots, M. L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peters, S. A. E.</au><au>Palmer, M. K.</au><au>Grobbee, D. E.</au><au>Crouse, J. R.</au><au>O’Leary, D. H.</au><au>Raichlen, J. S.</au><au>Bots, M. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C‐reactive protein lowering with rosuvastatin in the METEOR study</atitle><jtitle>Journal of internal medicine</jtitle><addtitle>J Intern Med</addtitle><date>2010-08</date><risdate>2010</risdate><volume>268</volume><issue>2</issue><spage>155</spage><epage>161</epage><pages>155-161</pages><issn>0954-6820</issn><eissn>1365-2796</eissn><abstract>. Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Caritas Carney Hospital, Boston, MA, USA; AstraZeneca, Wilmington, DE, USA). C‐reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155–161.
Objectives. In addition to its LDL‐C‐lowering effects, statin treatment reduces the level of C‐reactive protein (CRP). Long‐term data on this effect in low‐risk populations are limited. Furthermore, whether the CRP reduction is a consequence of LDL‐C lowering or occurs independently remains unclear. We studied these aspects in the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study, a randomized placebo‐controlled trial amongst 984 low‐risk subjects.
Methods. METEOR is a randomized placebo‐controlled trial that evaluated the effect of 40 mg of rosuvastatin on 2‐year change in carotid intima media thickness (CIMT) amongst 984 low‐risk patients (10‐year Framingham risk <10%) with modest CIMT (CIMT ≥ 1.2 and <3.5 mm) and elevated LDL‐C. CRP levels were measured at baseline and after 2 years of treatment.
Results. Median baseline CRP was 1.4 mg L–1. Rosuvastatin lowered CRP significantly compared with placebo: −36% in the rosuvastatin group versus no change in the placebo group. There was no relation between change in CRP and change in LDL‐C (Spearman correlation: 0.08; SE: 0.04). Stratified analyses showed that the CRP‐lowering effect was present amongst all strata of baseline characteristics, including baseline lipids and CRP levels. However, the magnitude of CRP reduction was larger amongst women and participants older than 60 years.
Conclusions. Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL‐C in low‐risk subjects with normal baseline CRP levels and modest CIMT.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20412373</pmid><doi>10.1111/j.1365-2796.2010.02230.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6820 |
| ispartof | Journal of internal medicine, 2010-08, Vol.268 (2), p.155-161 |
| issn | 0954-6820 1365-2796 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733996168 |
| source | MEDLINE; Wiley Online Library Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Aged Atherosclerosis - blood Atherosclerosis - prevention & control Biological and medical sciences Biomarkers - blood C-Reactive Protein - metabolism Carotid Arteries - drug effects Carotid Arteries - pathology carotid intima media thickness Cholesterol, LDL - blood Cholesterol, LDL - drug effects clinical trials Double-Blind Method Female Fluorobenzenes - pharmacology Fluorobenzenes - therapeutic use General aspects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use inflammation Male Medical sciences Middle Aged preventive medicine Pyrimidines - pharmacology Pyrimidines - therapeutic use Rosuvastatin Calcium statins Sulfonamides - pharmacology Sulfonamides - therapeutic use Tunica Intima - drug effects Tunica Intima - pathology Tunica Media - drug effects Tunica Media - pathology ultrasound |
| title | C‐reactive protein lowering with rosuvastatin in the METEOR study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A26%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C%E2%80%90reactive%20protein%20lowering%20with%20rosuvastatin%20in%20the%20METEOR%20study&rft.jtitle=Journal%20of%20internal%20medicine&rft.au=Peters,%20S.%20A.%20E.&rft.date=2010-08&rft.volume=268&rft.issue=2&rft.spage=155&rft.epage=161&rft.pages=155-161&rft.issn=0954-6820&rft.eissn=1365-2796&rft_id=info:doi/10.1111/j.1365-2796.2010.02230.x&rft_dat=%3Cproquest_cross%3E733996168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733996168&rft_id=info:pmid/20412373&rfr_iscdi=true |